OpenAlex
PricingAboutJobs
Log inGet started
Work

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*

HTML

Year: 2004
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Menopause The Journal of The North American Menopause Society
DOI: 10.1097/01.gme.0000119981.77837.1f
Authors: Marjorie Luckey, Risa Kagan, Susan Greenspan, Henry Bone, R. Douglas P. Kiel, James Simon, Jennifer Sackarowitz, Joanne Palmisano, Erluo Chen, Richard A. Petruschke, Anne E. de Papp
Institutions: Saint Barnabas Medical Center, Beth Israel Deaconess Medical Center, George Washington University, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English

Topic: Bone health and osteoporosis research
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Keywords: postmenopausal osteoporosis, alendronate, raloxifene, bisphosphonates, selective estrogen receptor modulators, bone mineral density, lumbar spine, hip, trochanter, bone turnover markers, N-terminal telopeptide of type I collagen, bone-specific alkaline phosphatase, safety and tolerability
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2070769074
FWCI: 5.903
Cites: 40
Cited by: 61
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security